SEC Comment Letter 0000000000-23-011689 to EyePoint Pharmaceuticals, Inc. (EYPT) (CIK 0001314102) (EYPT)
EyePoint Pharmaceuticals, Inc. (EYPT) (CIK 0001314102)
Date: Oct. 25, 2023 · CIK: 0001314102 · Accession: 0000000000-23-011689
AI Filing Summary & Sentiment
File numbers found in text: 333-275125
Letter
United States securities and exchange commission logo October 25, 2023 Ron Honig Chief Legal Officer EyePoint Pharmaceuticals, Inc. 480 Pleasant Street Watertown, MA 02472 Re:EyePoint Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed October 20, 2023 File No. 333-275125 Dear Ron Honig: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jane Park at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Stephen Nicolai, Esq.
Show Raw Text
United States securities and exchange commission logo
October 25, 2023
Ron Honig
Chief Legal Officer
EyePoint Pharmaceuticals, Inc.
480 Pleasant Street
Watertown, MA 02472
Re:EyePoint Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed October 20, 2023
File No. 333-275125
Dear Ron Honig:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Stephen Nicolai, Esq.